Publications

  1. Vora S, Pafundi D, Voss M, Buras M, Ashman J, Bendok B, Breen W, Hu L, Kizilbash S, Laack N, Liu W, Mahajan A, Mrugala M, Porter A, Ruff M, Sio T, Uhm J, Yang M, Brinkmann D, Brown P. Short-course hypofractionated proton beam therapy, incorporating (18)F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial. Lancet Oncol. 2024 Nov 18 [Epub ahead of print]
    View PubMed
  2. Sarkaria JN, Ballman KV, Kizilbash SH, Sulman EP, Giannini C, Friday BB, Butowski NA, Mohile NA, Piccioni DE, Battiste JD, Drappatz J, Campian JL, Mashru S, Jaeckle KA, O'Brien BJ, Dixon JG, Kabat BF, Laack NL, Hu LS, Kaufmann T, Kumthekar P, Ellingson BM, Anderson SK, Galanis E. Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial. JAMA Oncol. 2024 Oct 31 [Epub ahead of print]
    View PubMed
  3. Vora SA, Pafundi DH, Voss MM, Buras MR, Ashman JB, Bendok BR, Breen W, Hu LS, Kizilbash SH, Laack NN, Liu W, Mahajan A, Mrugala MM, Porter Umphrey AB, Ruff MW, Sio TT, Uhm J, Yang M, Brinkmann DH, Brown PD. Phase 2 Study of Short-Course, Hypofractionated Proton Beam Therapy Incorporating 18F-DOPA PET–MRI for Older Patients With Newly Diagnosed Glioblastoma (In review with Editor, Manuscript Number: D-24-00665R1) The Lancet. 2024.
  4. Desai A, Xiao AH, Choi D, Toruner MD, Walden D, Halfdanarson TR, Alberts S, McWilliams RR, Mahipal A, Ahn D, Babiker H, Stybayeva G, Revzin A, Kizilbash S, Adjei A, Bekaii-Saab T, Mansfield AS, Carr RM, Ma WW. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2024 May 13; 16 (10)
    View PubMed
  5. Sener U, Webb M, Breen WG, Neth BJ, Laack NN, Routman D, Brown PD, Mahajan A, Frechette K, Dudek AZ, Markovic SN, Block MS, McWilliams RR, Dimou A, Kottschade LA, Montane HN, Kizilbash SH, Campian JL. Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma. J Immunother Precis Oncol. 2024 Feb; 7 (1):1-6 Epub 2024 Feb 05
    View PubMed
  6. Sener U, Islam M, Webb M, Kizilbash SH. Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design. Neurooncol Adv. 2024 Jan-Dec; 6 (1):vdae039 Epub 2024 Mar 15
    View PubMed
  7. Riviere-Cazaux C, Rajani K, Rahman M, Oh J, Brown DA, White JF, Himes BT, Jusue-Torres I, Rodriguez M, Warrington AE, Kizilbash SH, Elmquist WF, Burns TC. Methodological and analytical considerations for intra-operative microdialysis. Fluids Barriers CNS. 2023 Dec 19; 20 (1):94
    View PubMed
  8. Riviere-Cazaux C, Carlstrom LP, Neth BJ, Olson IE, Rajani K, Rahman M, Ikram S, Mansour MA, Mukherjee B, Warrington AE, Short SC, von Zglinicki T, Brown DA, Burma S, Tchkonia T, Schafer MJ, Baker DJ, Kizilbash SH, Kirkland JL, Burns TC. An untapped window of opportunity for glioma: targeting therapy-induced senescence prior to recurrence. NPJ Precis Oncol. 2023 Nov 29; 7 (1):126
    View PubMed
  9. Riviere-Cazaux C, Neth BJ, Hoplin MD, Wessel B, Miska J, Kizilbash SH, Burns TC. Glioma Metabolic Feedback In Situ: A First-In-Human Pharmacodynamic Trial of Difluoromethylornithine + AMXT-1501 Through High-Molecular Weight Microdialysis. Neurosurgery. 2023 Oct 1; 93 (4):932-938 Epub 2023 May 29
    View PubMed
  10. Neth BJ, Raghunathan A, Kizilbash SH, Uhm JH, Breen WG, Johnson DR, Daniels DJ, Sener U, Carabenciov ID, Campian JL, Khatua S, Mahajan A, Ruff MW. Management and Long-term Outcomes of Adults With Medulloblastoma: A Single-Center Experience. Neurology. 2023 Sep 19; 101 (12):e1256-e1271 Epub 2023 July 31
    View PubMed
  11. Hong S, Atkinson JL, Erickson D, Kizilbash SH, Little JT, Routman DM, Van Gompel JJ. Treatment outcome of metastasis to the pituitary gland: a case series of 21 patients with pathological diagnosis. Neurosurg Focus. 2023 Aug; 55 (2):E13
    View PubMed
  12. Riviere-Cazaux C, Carlstrom LP, Rajani K, Munoz-Casabella A, Rahman M, Gharibi-Loron A, Brown DA, Miller KJ, White JJ, Himes BT, Jusue-Torres I, Ikram S, Ransom SC, Hirte R, Oh JH, Elmquist WF, Sarkaria JN, Vaubel RA, Rodriguez M, Warrington AE, Kizilbash SH, Burns TC. Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomas. Commun Biol. 2023 Jun 20; 6 (1):653 Epub 2023 June 20
    View PubMed
  13. Hong S, Atkinson JL, Erickson D, Kizilbash SH, Little JT, Routman DM, Van Gompel JJ. Contemporary Treatment Outcome of Metastases to the Pituitary Gland. World Neurosurg. 2023 Apr; 172:e684-e694 Epub 2023 Feb 09
    View PubMed
  14. Riviere-Cazaux C, Lacey JM, Carlstrom LP, Laxen WJ, Munoz-Casabella A, Hoplin MD, Ikram S, Zubair AB, Andersen KM, Warrington AE, Decker PA, Kaufmann TJ, Campian JL, Eckel-Passow JE, Kizilbash SH, Tortorelli S, Burns TC. Cerebrospinal fluid 2-hydroxyglutarate (2-HG) as a monitoring biomarker for IDH-mutant gliomas. medRxiv. 2023 Mar 2.
  15. Fortin Ensign SP, Jenkins RB, Giannini C, Sarkaria JN, Galanis E, Kizilbash SH. Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma. Neuro Oncol. 2023 Jan 5; 25 (1):28-36
    View PubMed
  16. Riviere-Cazaux C, Lacey JM, Carlstrom LP, Laxen WJ, Munoz-Casabella A, Hoplin MD, Ikram S, Zubair AB, Andersen KM, Warrington AE, Decker PA, Kaufmann TJ, Campian JL, Eckel-Passow JE, Kizilbash SH, Tortorelli S, Burns TC. Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas. Neurooncol Adv. 2023 Jan-Dec; 5 (1):vdad061 Epub 2023 May 11
    View PubMed
  17. Webb MJ, Neth BJ, Webb LM, Van Gompel JJ, Link MJ, Neff BA, Carlson ML, Driscoll CL, Dornhoffer J, Ruff MW, Anderson KA, Kizilbash SH, Campian JL, Uhm JH, Lane JI, Benson JC, Blezek DJ, Mehta PM, Bathla G, Sener UT. Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad123. Epub 2023 Sep 22.
    View PubMed
  18. Webb M, Johnson DR, Mahajan A, Brown P, Neth B, Kizilbash SH, Sener U. Clinical experience and outcomes in patients with pineal parenchymal tumor of intermediate differentiation (PPTID): a single-institution analysis. J Neurooncol. 2022 Nov; 160 (2):527-534 Epub 2022 Oct 27
    View PubMed
  19. Ramos-Fresnedo A, Domingo RA, Perez-Vega C, Pullen MW, Akinduro OO, Almeida JP, Jentoft ME, Bendok BR, Chaichana KL, Trifiletti DM, Burns TC, Porter AB, Kizilbash SH, Middlebrooks EH, Quiñones-Hinojosa A, Sherman WJ. The early infiltrative phase of GBM hypothesis: are molecular glioblastomas histological glioblastomas in the making? A preliminary multicenter study. J Neurooncol. 2022 Jul; 158(3):497-506. Epub 2022 Jun 14.
    View PubMed
  20. Breen WG, Youland RS, Giri S, Jacobson SB, Pafundi DH, Brown PD, Hunt CH, Mahajan A, Ruff MW, Kizilbash SH, Uhm JH, Routman DM, Jones JE, Brinkmann DH, Laack NN. Initial results of a phase II trial of (18)F-DOPA PET-guided re-irradiation for recurrent high-grade glioma. J Neurooncol. 2022 Jul; 158 (3):323-330 Epub 2022 May 18
    View PubMed
  21. Li JJ, Zhang X, Sankar N, Espiritu L, Redkar S, Yu GL, Kizilbash SH. MET/HGF Coexpression as a Novel Predictive Biomarker for Response to MET Inhibitor Therapy in a Case of Psammomatous Melanotic Schwannoma. JCO Precis Oncol. 2022 Jun; 6:e2200096
    View PubMed
  22. Neth BJ, Balakrishnan SN, Carabenciov ID, Uhm JH, Daniels DJ, Kizilbash SH, Ruff MW. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience. J Neurooncol. 2022 Mar; 157 (1):91-100 Epub 2022 Jan 25
    View PubMed
  23. Ramos-Fresnedo A, Pullen MW, Perez-Vega C, Domingo RA, Akinduro OO, Almeida JP, Suarez-Meade P, Marenco-Hillembrand L, Jentoft ME, Bendok BR, Trifiletti DM, Chaichana KL, Porter AB, Quiñones-Hinojosa A, Burns TC, Kizilbash SH, Middlebrooks EH, Sherman WJ. The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study. J Neurooncol. 2022 Mar; 157(1):177-185. Epub 2022 Feb 17.
    View PubMed
  24. Porter AB, Liu H, Kohli S, Cerhan JL, Sloan J, McMurray RP, Le-Rademacher J, Loprinzi CL, Villano JL, Kizilbash SH, Mehta MP, Jaeckle KA, Brown PD. Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Feb 1; 8 (2):259-267
    View PubMed
  25. Kerezoudis P, Yolcu YU, Laack NN, Ruff MW, Khatua S, Daniels DJ, Burns TC, Kizilbash SH. Survival and associated predictors for patients with pineoblastoma or pineal parenchymal tumors of intermediate differentiation older than 3 years: Insights from the National Cancer Database. Neurooncol Adv. 2022 Jan-Dec; 4 (1):vdac057 Epub 2022 Apr 17
    View PubMed
  26. Laack NN, Pafundi D, Anderson SK, Kaufmann T, Lowe V, Hunt C, Vogen D, Yan E, Sarkaria J, Brown P, Kizilbash S, Uhm J, Ruff M, Zakhary M, Zhang Y, Seaberg M, Wan Chan Tseung HS, Kabat B, Kemp B, Brinkmann D. Initial Results of a Phase 2 Trial of (18)F-DOPA PET-Guided Dose-Escalated Radiation Therapy for Glioblastoma. Int J Radiat Oncol Biol Phys. 2021 Aug 1; 110 (5):1383-1395 Epub 2021 Mar 23
    View PubMed
  27. Eschbacher KL, Ida CM, Johnson DR, Alvi MA, Jenkins SM, Ruff MW, Kerezoudis P, Neth BJ, Pasion RM, Daniels DJ, Kizilbash SH, Raghunathan A. Diffuse Gliomas of the Brainstem and Cerebellum in Adults Show Molecular Heterogeneity. Am J Surg Pathol. 2021 Aug 1; 45 (8):1082-1090
    View PubMed
  28. Kizilbash SH, Gupta SK, Parrish KE, Laramy JK, Kim M, Gampa G, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Elmquist WF, Sarkaria JN. In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling. Mol Cancer Ther. 2021 Jun; 20 (6):1009-1018 Epub 2021 Mar 30
    View PubMed
  29. Zahid A, Johnson DR, Kizilbash SH. Efficacy of (177)Lu-Dotatate Therapy in the Treatment of Recurrent Meningioma. Mayo Clin Proc Innov Qual Outcomes. 2021 Feb; 5 (1):236-240 Epub 2021 Jan 14
    View PubMed
  30. Zreik J, Kerezoudis P, Alvi MA, Yolcu YU, Kizilbash SH. Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database. Front Oncol. 2021; 11:746844 Epub 2021 Nov 09
    View PubMed
  31. Ruff M, Kizilbash S, Buckner J. Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development. Expert Rev Anticancer Ther. 2020 May; 20 (5):355-363 Epub 2020 May 12
    View PubMed
  32. Kerezoudis P, Goyal A, Lu VM, Alvi MA, Bydon M, Kizilbash SH, Burns TC. The role of radiation and chemotherapy in adult patients with high-grade brainstem gliomas: results from the National Cancer Database. J Neurooncol. 2020 Jan; 146 (2):303-310 Epub 2019 Dec 24
    View PubMed
  33. Ruff MW, Kizilbash SH. Glioblastoma with bilateral extraocular muscle infiltration preceded by evidence of vascular tropism. J Clin Neurosci. 2019 Mar; 61:277-278 Epub 2018 Nov 22
    View PubMed
  34. Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, Elmquist WF. Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. Pharm Res. 2018 Jul 12; 35 (9):177 Epub 2018 July 12
    View PubMed
  35. Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 2018 Jan 22; 20 (2):184-191
    View PubMed
  36. Gupta SK, Smith EJ, Mladek AC, Tian S, Decker PA, Kizilbash SH, Kitange GJ, Sarkaria JN. PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity. Front Oncol. 2018; 8:670 Epub 2019 Jan 22
    View PubMed
  37. Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Kitange GJ, Shen Y, Feng Y, Protter AA, Elmquist WF, Sarkaria JN. Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Mol Cancer Ther. 2017 Dec; 16 (12):2735-2746 Epub 2017 Sept 25
    View PubMed
  38. Shin JY, Kizilbash SH, Robinson S, Uhm JH, Jatoi A. Incidence, Characteristics, and Implications of Seizures in Patients With Glioblastoma. Am J Hosp Palliat Care. 2017 Aug; 34 (7):650-653 Epub 2016 May 05
    View PubMed
  39. Zahid MF, Khan N, Hashmi SK, Kizilbash SH, Barta SK. Central nervous system prophylaxis in diffuse large B-cell lymphoma. Eur J Haematol. 2016 Aug; 97 (2):108-20 Epub 2016 May 25
    View PubMed
  40. Shin JY, Kizilbash SH, Robinson SI, Uhm JH, Hammack JE, Lachance DH, Buckner JC, Jatoi A. Seizures in patients with primary brain tumors: what is their psychosocial impact? J Neurooncol. 2016 Jun; 128 (2):285-91 Epub 2016 Mar 15
    View PubMed
  41. Gupta SK, Kizilbash SH, Carlson BL, Mladek AC, Boakye-Agyeman F, Bakken KK, Pokorny JL, Schroeder MA, Decker PA, Cen L, Eckel-Passow JE, Sarkar G, Ballman KV, Reid JM, Jenkins RB, Verhaak RG, Sulman EP, Kitange GJ, Sarkaria JN. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. J Natl Cancer Inst. 2016 May; 108 (5) Epub 2015 Nov 27
    View PubMed
  42. Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NY, Curtin NJ, Elmquist WF, Sarkaria JN. Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Mol Cancer Ther. 2015 Dec; 14 (12):2735-43 Epub 2015 Oct 05
    View PubMed
  43. Kizilbash SH, Giannini C, Voss JS, Decker PA, Jenkins RB, Hardie J, Laack NN, Parney IF, Uhm JH, Buckner JC. The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. J Neurooncol. 2014 Oct; 120 (1):85-93 Epub 2014 July 04
    View PubMed
  44. Gupta SK, Mladek AC, Carlson BL, Boakye-Agyeman F, Bakken KK, Kizilbash SH, Schroeder MA, Reid J, Sarkaria JN. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clin Cancer Res. 2014 Jul 15; 20 (14):3730-41 Epub 2014 May 16
    View PubMed
  45. Kizilbash SH, Ward KC, Liang JJ, Jaiyesimi I, Lipscomb J. Survival outcomes in patients with early stage, resected pancreatic cancer - A comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens. Int J Clin Pract. 2014; 68(5):578-89.
    View PubMed
  46. Liang JJ, Kizilbash SH, Haluska P. Intrathecal metastases causing conus medullaris syndrome. QJM. 2014 Jan; 107: (1)75.
    View PubMed
  47. Dhamija R, Nickels KC, Calero A, Doraiswamy B, Rosenberg J, Kizilbash SH, Kizilbash SJ, Agrawal R. Case 1: Foot deformities, asymmetric calf muscles, and frequent falls in an 8-year-old boy. Case 2: Seizures in a 5-month-old boy whose mother recently emigrated from Honduras. Case 3: A gradually increasing perianal mass in a teenage girl. Pediatr Rev. 2011 Apr; 32 (4):163-8
    View PubMed
  48. Agrawal V, Kizilbash S, McCullough P. New therapeutic agents for diabetic kidney disease Therapy. July 2008; 5(4):553-575.